SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Isotechnika
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (52)5/22/2003 10:07:31 PM
From: teevee  Read Replies (1) of 285
 
Biomaven,
Thanks for the clarification. I was thinking about the "bottleneck" on all organ transplantation because of renal toxicity, which means that as the total number of transplantees increases, existing transplant patients use an ever increasing percentage of available kidneys. I know many transplant patients are on their second, third and even fourth kidneys. Transfering existing transplant patients to a new drug without renal toxicity, would allow for more transplants overall. Would this not be an unmet need from the perspective that more kidneys would be available for new kidney patients requiring them and no more kidneys would be required for patients receiving other organ transplants such as heart, lung and liver? Would this not allow for more life saving transplant operations? Thanks for your comments.

cheers,
teevee
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News